Breaking News, Collaborations & Alliances

CMAB Completes Devt. and Mfg. Project for QureBio

Bispecific antibody Q-1802 will enter clinical trials to assess treatment of solid tumors such as gastric cancer

By: Contract Pharma

Contract Pharma Staff

CMAB Biopharma (Suzhou) Inc., a company exclusively focused on delivering contract development and manufacturing services for biologics, said that it has successfully completed the development and manufacturing of QureBio’s bispecific antibody Q-1802 in only 9 months through its fully integrated platform. The filing package and drug product conforms to requirements necessary to submit INDs in both China and the U.S. Q-1802 is a bispecific antibody being studied for the treatment of solid t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters